Corporate strategy executive working with payers and providers focused on growth, planning and performance improvement
Deep transaction and development experience from deal sourcing to post-merger integration
Charlotte
@alvarezmarsal
LinkedIn
Copied!
Erik Swanson is a Managing Director with Alvarez & Marsal’s Healthcare Industry Group in Charlotte. He brings more than 25 years of experience working with payers and providers across strategic planning, performance improvement, growth and transactions.
Mr. Swanson works with large national payers, regional not-for-profit health plans and integrated systems across multiple functional areas including care management, medical management, claims, network and sales/distribution. He has evaluated care management efficacy across Medicare and commercial businesses, driven claims savings through root cause analysis of inaccurate payments and associated remediation, defined effective customer segmentation to support tailored sales and growth and led corporate development efforts across partnerships and acquisitions.
Prior to joining A&M, Mr. Swanson was a Managing Director with EY-Parthenon in the healthcare group. He served both payer and provider clients, supporting them through strategic projects ranging from transactions and growth strategy to performance improvement. Previously, Mr. Swanson served in industry roles at Premier, Inc., and Elevance, supporting corporate strategy and development.
Mr. Swanson started his consulting career at Accenture and became a Partner in the health and life sciences practice. He also spent five years in investment banking.
Mr. Swanson earned a bachelor’s degree in economics from Duke University and an MBA from Emory University.
In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.
Medicare Advantage (MA) enrollment exceeds 33 million members, represents $450B in payments from the Federal government, and is expected to double over the next 10 years. Yet, changes to the MA program have reduced overall profitability and challenged payers to adapt.
Home-based healthcare can deliver better outcomes, at lower cost, and with a better patient experience. Technology exists to enable the most sophisticated solutions, yet, post-pandemic adoption of virtual services, including hospital at home and many consults, has waned.
Latest insightsThe latest insights from Erik Swanson's team
Medical device supply chains are under increasing pressure as global disruption becomes a constant rather than an exception. From geopolitical volatility to material scarcity and regulatory complexity, the sector now operates in an environment where even minor shocks can have far-reaching consequences. This article explores the structural vulnerabilities shaping today’s MedTech supply networks and highlights why traditional approaches are no longer sufficient. It outlines how leading organisations are rethinking resilience not just as risk mitigation, but as a source of competitive advantage in an increasingly unpredictable world. Download the full article to uncover the strategies that are helping companies respond faster, protect patient outcomes, and maintain operational continuity.